J. Kelly Ganjei
President & Chief Executive Officer
Kelly is a biopharmaceutical leader, with more than 26 years of experience ranging from the bench to the boardroom, with more than 17 years in the cell and gene therapy area.
EVP and Chief Commercial Officer
Jerry Hacker has more than 25 years of executive-level experience within health and life sciences, leading global sales, marketing, operations, customer support and M&A.
Harry Ledebur, Ph.D.
VP & General Manager of Discovery, Safety and Efficacy Services
Harry Ledebur, Ph.D., leads clinical and non-clinical research programs, including the testing, characterization and development of therapeutics.
Jaehyung (“Jae”) Yoon
EVP, Finance and Strategy
Jae Yoon has more than 20 years of experience spanning bench research, venture capital, corporate finance, and corporate strategy and development.
VP, Information Systems
Karim brings more than 15 years of experience in information technology management and operations.
Roy Barnewall, DVM, Ph.D.
Director of Veterinary Sciences, Non-clinical Toxicology and Safety Pharmacology
Roy Barnewall, DVM, Ph.D., has nearly three decades of experience in veterinary medicine and pre-clinical research.
Director of Business Development
Mark is a business development executive with 25 years of contract research and instrumentation experience.
Manager of Quality Assurance
Claire Freitag has over 10 years of experience working in non-clinical laboratory research, regulatory compliance and FDA-GLP.
Director of Operations
Greg Kastner has decades of experience managing operations and program management of complex research projects.
Director of Study Oversight
Dean has over two decades of experience in the conduct of integrated non-clinical studies including toxicology and pharmacology.
Sabrina McGraw, DVM, Ph.D.
Director of Pathology
Sabrina McGraw, DVM, Ph.D., is an ACVP board-certified anatomic pathologist and project manager with more than a decade of experience in pathology and complex program management.